Sleep apnoea and weight loss are more closely connected than most men realise, and understanding that link could change how you sleep, how you feel, and how long you live. If you've been told you snore badly, wake up exhausted after a full night, or your partner has noticed you stop breathing in the night, excess weight is almost certainly part of the story. This article explains what obstructive sleep apnoea is, why it hits men harder, how much weight loss genuinely matters, and what the evidence says about GLP-1 medications like Wegovy and Mounjaro.
What Is Obstructive Sleep Apnoea and Why Does It Hit Men Harder?
Obstructive sleep apnoea (OSA) happens when the soft tissue at the back of your throat collapses during sleep, repeatedly blocking your airway. Each time it collapses, your brain briefly wakes you to restart breathing. You may not remember it, but your body registers every episode.
The consequences go well beyond tiredness. Untreated OSA raises your risk of high blood pressure, cardiovascular disease, type 2 diabetes, and depression. It also drives weight gain, which in turn worsens the apnoea - a self-reinforcing cycle most men never trace back to a single cause.
Men are two to three times more likely to develop OSA than women. Part of the reason is anatomical: men tend to carry more fat around the neck and upper airway, and male hormones affect how the airway muscles behave during sleep. But the biggest driver is metabolic. Excess abdominal and neck fat increases the mechanical load on the airway, and as BMI rises, so does the severity of apnoea events.
Severe untreated OSA is linked to a significantly higher risk of cardiovascular death. Yet most men with the condition remain undiagnosed - partly because the symptoms are easy to normalise, and partly because seeking help can feel like admitting something is wrong.
The Weight–Sleep Apnoea Loop
The relationship between weight and OSA runs both ways. Excess weight increases your likelihood of developing OSA - and OSA itself makes weight harder to lose.
Fragmented sleep disrupts the hormones that regulate appetite, ghrelin and leptin. When you're chronically sleep-deprived, ghrelin (which drives hunger) rises and leptin (which signals fullness) falls. The result: you feel hungrier, crave higher-calorie food, and have less resolve to resist it. Add the fatigue that makes exercise feel impossible, and you have a cycle that's genuinely hard to break through diet alone.
This is why many men with OSA struggle to lose weight even when they're trying - the condition is working against them at a hormonal level. Breaking the loop means addressing both sides at once: treating the sleep disruption while tackling the weight that caused it.
How Much Does Weight Loss Actually Improve Sleep Apnoea?
The evidence is clear and consistent: weight loss reduces the severity of obstructive sleep apnoea, and in some cases resolves it.
A widely cited benchmark is that a 10% reduction in body weight corresponds to roughly a 26% reduction in the apnoea-hypopnoea index (AHI), the measure used to grade OSA severity. For men with moderate to severe OSA, meaningful weight loss can shift them out of the category that requires CPAP, or reduce the pressure settings they need.
The effect is most pronounced in men who are overweight or obese. Where excess fat around the neck and airway is contributing to the obstruction, losing that fat directly reduces the mechanical pressure on the airway during sleep.
Weight loss is not a guaranteed cure. Some men have structural factors that contribute to OSA independently of weight, and the degree of improvement varies. But for most men with OSA and a BMI above 27, losing weight is one of the most clinically meaningful things they can do.
CPAP Is a Treatment, Not a Solution
CPAP (Continuous Positive Airway Pressure) is the most widely prescribed treatment for moderate to severe OSA. It pumps pressurised air through a mask to keep the airway open during sleep. For many men it's genuinely life-changing - the snoring stops, daytime fatigue lifts, and cardiovascular risk falls.
But CPAP manages the symptom rather than the cause. Stop using the machine and the apnoea returns. Compliance is also a real issue: a significant proportion of patients either abandon CPAP within the first year or use it for fewer hours than recommended.
Weight loss addresses the metabolic root. A man who loses 15% of his body weight on a clinically supervised programme may find his OSA improves to the point where CPAP is no longer needed - or that the machine becomes easier to tolerate because the underlying obstruction has eased. For most men with OSA and excess weight, the most effective approach isn't CPAP alone or weight loss alone. It's both: weight loss addressing the cause while CPAP manages the immediate risk.
GLP-1 Medications and Sleep Apnoea: What the Evidence Shows
The arrival of GLP-1 receptor agonists - semaglutide (Wegovy) and tirzepatide (Mounjaro) - has changed what's clinically possible for men with obesity-related sleep apnoea.
These medications mimic hormones that regulate appetite and blood sugar. They reduce hunger, slow digestion, and produce substantial, sustained weight loss in most patients - well beyond what lifestyle change alone tends to achieve.
The evidence in OSA specifically is now strong. In the SURMOUNT-OSA trials (published in the New England Journal of Medicine in 2024), tirzepatide produced a large reduction in AHI in adults with obesity and moderate-to-severe OSA - a treatment difference of around 20 events per hour in men not using CPAP, and around 24 events per hour in those on CPAP, over 52 weeks. Those AHI reductions tracked closely with the amount of weight lost; whether tirzepatide also acts directly on the airway is still being investigated rather than established.
On the strength of that data, tirzepatide (marketed as Zepbound) became the first medication approved specifically for OSA in the US, in December 2024. It is not currently licensed for OSA in the UK, where it remains a weight-management treatment - but for men whose OSA is driven by excess weight, treating that weight is treating the apnoea.
Why Blood Testing Matters Before You Start
Starting a GLP-1 medication without understanding your metabolic baseline is like treating symptoms without a diagnosis. You know you want to lose weight - but you don't know whether your liver is already under strain, whether your testosterone is low, whether your cardiovascular markers are raised, or how your thyroid is functioning.
All of these affect how you respond to treatment, what side effects you might experience, and what your real risks are. A man with elevated liver enzymes needs different monitoring from one whose liver function is normal. A man with low testosterone alongside obesity is dealing with a different hormonal picture from one without it.
This is the gap most online weight loss services leave unfilled. They prescribe from a questionnaire: a clinician reviews your answers and approves the medication, but no one has looked at what's actually happening inside your body.
HeMed works differently. Before any prescription, you complete a needle-free at-home blood test measuring 10 metabolic markers across cardiovascular risk, liver function, diabetes risk, and thyroid function. A registered clinician reviews your results and builds a plan around your actual biology, with follow-up tests every six months so your prescription can be adjusted as your body changes.
This matters especially for men with sleep apnoea, because OSA rarely travels alone. It tends to cluster with raised blood pressure, insulin resistance, high triglycerides, and low testosterone. Treating the weight without seeing the full picture means flying blind.
The Five Conditions That Travel Together
Sleep apnoea is one of five metabolic conditions that disproportionately affect men and often occur together. The others are obesity, cardiovascular disease, silent liver disease (MASLD), and low testosterone.
These aren't separate problems. They share common upstream causes - chiefly excess visceral fat and the hormonal and inflammatory disruption that comes with it. A man with OSA and a BMI of 32 is statistically likely to have at least one of the other four, often without knowing.
That's why a programme addressing only one condition at a time is inherently limited. Losing weight while ignoring testosterone, liver health, and cardiovascular markers is an incomplete fix. The most effective approach treats the full metabolic picture - which is what a programme built around blood diagnostics, rather than a questionnaire, can do.
What to Expect from a Medically Supervised Weight Loss Programme
If you're a UK man with suspected or confirmed OSA and a BMI above 27, here's what a clinically supervised programme typically involves:
- Eligibility assessment. Questions about your health history, current medications, and goals determine whether GLP-1 medication is appropriate.
- Baseline blood testing. A metabolic panel establishes your starting point across key markers — not optional if you want a genuinely personalised prescription.
- Clinician review. A registered clinician reviews your results and history before prescribing, and selects the medication and starting dose for your profile.
- Prescription delivery. Medication delivered to your home, typically next-day, in discreet packaging.
- Ongoing support and monitoring. Regular check-ins, in-app progress tracking, and a follow-up blood test at six months.
- Dose adjustment. GLP-1 medications are titrated upward over time, with your clinician adjusting based on your response and your blood results rather than a fixed protocol.
Through HeMed, plans start from £59 per month on a 12-month plan, with all blood tests, clinical support, delivery, and app access included. Diagnostics are bundled into the subscription rather than charged separately, so you're not paying extra for the blood testing that should be central to any responsible treatment. (Pricing is correct at the time of publishing.)
Why This Is Particularly Urgent for Men
UK men live, on average, around four years less than women. A significant part of that gap is explained by metabolic conditions that go undetected and untreated for years - often because men avoid healthcare until a crisis forces the issue.
Sleep apnoea is a case in point. Men normalise the snoring, put the fatigue down to work stress, and don't connect the morning headaches or low mood to a condition disrupting their breathing hundreds of times a night. By the time a diagnosis arrives, cardiovascular damage may already have begun, weight has continued to climb, and the conditions that travel with OSA have had years to develop.
Acting earlier, before the crisis, is the rational response to a well-established pattern.
A Practical Starting Point
If you recognise yourself in this article, the most useful first step isn't to book a sleep study or buy a CPAP machine. It's to understand your metabolic baseline.
Find out what your blood markers actually look like. Understand whether your weight is already affecting your liver, your heart, or your hormones. Then make a treatment decision based on your biology rather than a symptom checklist.
You can check your eligibility for clinician-supervised weight loss treatment at hemed.com.
Sleep apnoea is a serious condition - but for most men, the weight that drives it is treatable, and the clinical tools to do that properly are more effective than ever.
Frequently Asked Questions
Can losing weight cure sleep apnoea?
Weight loss can significantly reduce the severity of obstructive sleep apnoea and, in some cases, resolve it. For men with a BMI above 27 whose OSA is driven mainly by excess weight, meaningful weight loss often leads to measurable improvements in AHI. Results vary, and some men have structural factors that contribute to OSA independently of weight.
How much weight do I need to lose to improve my sleep apnoea?
Clinical evidence suggests a 10% reduction in body weight corresponds to roughly a 26% reduction in AHI. Even modest weight loss can shift you from a more severe category to a milder one, and greater weight loss tends to produce greater improvement.
Do Wegovy or Mounjaro help with sleep apnoea?
Yes. The main mechanism is weight loss, which reduces the neck and airway fat that contributes to obstruction. In the 2024 SURMOUNT-OSA trials, tirzepatide (Mounjaro) produced large AHI reductions in adults with obesity and OSA. Those reductions correlated closely with weight lost; a separate direct airway effect hasn't yet been confirmed.
Should I stop using CPAP if I lose weight?
No, not without medical guidance. CPAP manages the immediate risk of airway obstruction. As you lose weight your OSA may improve to the point where CPAP can be reduced or stopped, but this should be confirmed with a follow-up sleep assessment. Stopping prematurely can be dangerous.
Is sleep apnoea connected to low testosterone?
Yes. OSA and low testosterone frequently occur together, and the relationship runs both ways. Sleep deprivation from OSA lowers testosterone production, and low testosterone affects body composition, making fat easier to gain and harder to lose. Addressing both as part of a broader metabolic programme produces better outcomes than treating either alone.
Why do men with sleep apnoea struggle to lose weight?
OSA fragments sleep, which raises ghrelin (hunger) and suppresses leptin (fullness). That makes men with untreated OSA feel hungrier, crave higher-calorie food, and have less energy for activity. Breaking the cycle means addressing both the sleep disruption and the underlying weight.
What blood markers should be tested before starting?
At minimum, a useful panel covers cardiovascular risk markers, liver function, diabetes risk (including HbA1c and fasting glucose), thyroid function, and testosterone. These establish whether other conditions are present alongside OSA and help ensure any prescribed treatment fits your specific biology.
References
- Peppard PE, et al. Longitudinal Study of Moderate Weight Change and Sleep-Disordered Breathing. JAMA. 2000;284(23):3015–3021. DOI: 10.1001/jama.284.23.3015
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193–1205. DOI: 10.1056/NEJMoa2404881
- Taheri S, et al. Short Sleep Duration Is Associated with Reduced Leptin, Elevated Ghrelin, and Increased Body Mass Index. PLoS Medicine. 2004;1(3):e62. DOI: 10.1371/journal.pmed.0010062
- Office for National Statistics. National Life Tables, UK.
HeMed’s personalised weight loss programme uses medical treatment to help you achieve results that last.
